Sent from my BlackBerry® wireless handheld

From: Pharmacists_coffee <pharmacists_coffee@yahoo.com>

Sender: Pharmacists_coffee@yahoogroups.com

Date: Fri, 15 Apr 2011 17:37:23 +0200

ReplyTo: Pharmacists_coffee@yahoogroups.com

Cc: <pharmacists_coffee@yahoo.com>; <pharmacists_coffee@yahoogroups.com>

Subject: [PCM] Novartis Discontinues Clinical Trial of Tasigna� + Vacancies [1 Attachment]

[Attachment(s) from Pharmacists_coffee included below]

- To stop receiving newsletter, reply with "Stop"

- To subscribe to PCM newsletter click here

- To publish vacancy please click here

Home : Archive : Subscribe : Contact us : Upload CV : Invite friends : Publish Vacancy

Pharmacists_ coffee magazine
Electronic Edition
Edition No. 401, year 4
April 15, 2011
Today's edition sent to: 23,680 Arabian Pharmacists

Find Valuable attachment
"18 Ways to Plan Your Day"
may find attachment at the end of e-mail

Today in Hot pharma news

Medicine of the week

Ranitidine

Ranitidine (pronounced /rəˈnɪtɨdiːn/) (trade name Zantac) is a histamine H₂-receptor antagonist that inhibits stomach acid production. It is commonly used in treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Ranitidine is also used alongside fexofenadine and other antihistamines for the treatment of skin conditions such as hives.

Clinical use:

Certain preparations of ranitidine are available over the counter (OTC) in various countries. In the United States, 75 mg and 150 mg tablets are available OTC. Zantac OTC is manufactured by Boehringer Ingelheim. In Australia, packs containing 7 or 14 doses of the 150 mg tablet are available in supermarkets, small packs of 150 mg and 300 mg tablets are Schedule 2 Pharmacy Medicines. Larger doses and pack sizes still require a prescription.
Outside the United States, ranitidine is combined with bismuth (which acts as a mild antibiotic) as a citrate salt (ranitidine bismuth citrate, Tritec), to treat Helicobacter pylori infections. This combination is usually given with clarithromycin, an antibiotic.
Ranitidine's main role is in treating gastric and duodenal ulcers and gastroesophageal reflux disease. It is also used to treat pediatric reflux, where it is preferred over a PPI, because it does not induce histologically relevant hyperplastic changes in the parietal cells. Liquid formulations are available for administering to children.
Ranitidine can also be co-administered with NSAIDs to reduce the risk of ulceration.
Ranitidine can be administered preoperatively to reduce the risk of aspiration pneumonia. The drug not only increases gastric pH, but also reduces the total output of gastric juice. Ranitidine may have an antiemetic effect when administered preoperatively.
It can be administered IV in intensive care units to critically ill patients (particularly geriatric ones) to reduce the risk of gastric bleeding.
The usual dose of ranitidine is either 150 mg twice a day or 300 mg once every twenty four hours, usually at night. For ulcer treatment, a 300 mg nighttime dose is especialy important - as the increase in gastric/duodenal pH promotes healing overnight when the stomach and duodenum are empty. Conversely, for treating reflux, smaller and more frequent doses are more effective.
Ranitidine used to be administered long term for reflux treatment, sometimes indefinitely. However, PPIs have taken over this role.
In some patients with severe reflux, up to 600 mg of ranitidine can be administered daily, usually in 4 lots of 150 mg. Such a high dose was not unusual in the past, but nowadays a once-a-day PPI is used instead - both for convenience and because they are more effective in raising gastric pH. Patients with Zollinger-Ellison syndrome have been given doses of 6000 mg per day without any harm.
Ranitidine's main side effects are confusion and depression, although these are very rare and usually only seen in geriatric patients.

History and development:

Ranitidine was developed by Glaxo in an effort to match the success of Smith, Kline & French (prior to the merger of the two companies into GlaxoSmithKline) with the first histamine H₂-receptor antagonist cimetidine. Ranitidine was the result of a rational drug-design process using what was by then a fairly refined model of the histamine H₂-receptor and quantitative structure-activity relationships (QSAR).
Glaxo refined the model further by replacing the imidazole-ring of cimetidine with a furan-ring with a nitrogen-containing substituent, and in doing so developed ranitidine. Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and ten times the activity of cimetidine. Ranitidine has 10% the affinity that cimetidine has to CYP450 so it causes fewer side effects, but other H₂ blockers famotidine and nizatidine have no CYP450 significant interactions.^[1]
Ranitidine was introduced in 1981 and was the world's biggest-selling prescription drug by 1988. It has since largely been superseded by the even more effective proton pump inhibitors, with omeprazole becoming the biggest-selling drug for many years. When omeprazole and ranitidine were compared in a study of 144 people with severe inflammation and erosions or ulcers of the esophagus, 85% to those treated with omeprazole healed within eight weeks, compared to 50% of those given ranitidine. In addition, the omeprazole group reported earlier relief of heart burn symptoms.

KSA to KSA

+ Add a vacancy

Fresh Graduates Medical rep. – KSA

Medical Saudi Company have a different agencies in middle east especially Gulf region , The company Working scope is governmental hospitals to promote and distribute unique medical devices . Seeking a medical rep. with following requirements :

• Fresh Graduated Only .

• Ability to travel domestic and international .

• Transferable Iqama .

• Driving license .

• Resident in Jeddah .

Please send your C.V with recent photo within 1 week on :

الصيدلى العربى

Friday, April 15, 2011

Pharmacists Coffee [PCM] Novartis Discontinues Clinical Trial of Tasigna? + Vacancies [1 Attachment]

Bayer's Rivaroxaban Submitted for Approval in Japan

Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease

Forest Laboratories Completes Acquisition of Clinical Data, Inc.

Nycomed acquires distribution rights to product portfolio in Turkey

Novartis discontinues clinical trial of Tasigna®

Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled

Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease

Get More

No comments:

مصر اليوم

Slide Ads

منوعات عربية

Visitors

البيت بيتك

مكتبة الفيديو

Blog Archive

انشر هذا الموضوع على صفحتك